# US 2014/0030269 A1 · Staphylococcus aureus Specific Human Recombinant Polyclonal Antibodies and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0030269 A1
- Document ID: US20140030269A1
- Status: Published application
- Kind: A1
- Application number: 13/951,645
- Filed: 2013-07-26
- Published: 2014-01-30
- Earliest claimed: 2010-09-02
- Assignees: Excelimmune, Inc.
- Applicants: Excelimmune, Inc.
- Inventors: Vincent W. Coljee
- Web page: https://patentgrep.com/patent/US20140030269A1

## CPC

- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- A61P 31/04: Antibacterial agents
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/55: Fab or Fab'
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Human antibodies that bind to one or more strains Staphylococcus aureus strains, including methicillin resistant strains, are disclosed. Also disclosed are human recombinant polyclonal antibody compositions, and therapeutic methods for using the antibodies.

## Claims

### Claim at position 1

-44. (canceled)

### Claim 45

A method for treating or preventing Staphylococcus aureus (S. aureus) infection in a mammal, the method comprising administering an effective amount of a recombinant monoclonal antibody mixture, wherein the antibody mixture comprises at least two human antibodies, each of which binds to and neutralizes a S. aureus toxin or antigen conserved among at least three different strains of S. aureus;
and wherein each antibody in the antibody mixture binds an epitope that is not bound by another member of the antibody mixture.

### Claim 46 (depends on 45)

The method of claim 45, wherein the mammal is a human.

### Claim 47 (depends on 45)

The method of claim 45, wherein the Staphylococcus aureus infection is a methicillin-resistant Staphylococcus aureus (MRSA) infection.

### Claim 48 (depends on 45)

The method of claim 45, wherein the Staphylococcus aureus infection is a methicillin-sensitive Staphylococcus aureus (MSSA) infection.

### Claim 49 (depends on 45)

The method of claim 45, wherein the Staphylococcus aureus infection is a vancomycin-resistant Staphylococcus aureus (VRSA) infection.

### Claim 50 (depends on 45)

The method of claim 45, wherein the Staphylococcus aureus infection is a vancomycin-intermediate Staphylococcus aureus (VISA) infection.

### Claim 51

(canceled)

### Claim 52 (depends on 45)

The method of claim 45, wherein the antibody mixture comprises at least one of the antibodies identified in Table 2.

### Claim 53 (depends on 52)

The method of claim 52, wherein the antibody mixture comprises at least 3 of the antibodies identified in Table 2.

### Claim 54 (depends on 45)

The method of claim 45, wherein the at least three different strains of S. aureus includes at least one of the strains identified in Table 4.

### Claim 55 (depends on 54)

The method of claim 54, wherein the at least three different strains of S. aureus includes at least five of the strains identified in Table 4.

### Claim 56 (depends on 45)

The method of claim 45, wherein the antibody mixture comprises a combination of any two antibodies as set forth in Table 1.

### Claim 57 (depends on 45)

The method of claim 45, wherein at least one of the antibodies in the antibody mixture binds delta-toxin.

### Claim 58 (depends on 45)

The method of claim 45, wherein at least one of the antibodies in the antibody mixture binds toxin phenol soluble modulin beta-1.

### Claim 59 (depends on 45)

The method of claim 45, wherein at least one of the antibodies in the antibody mixture is selected from the group consisting of:
(a) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 38 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 40 of 5.6.H9;
(b) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 173 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 175 of 22.18A.E9;
(c) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 11 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 13 of 5.11.H10;
(d) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 20 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 22 of 5.27.A11;
(e) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 47 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 49 of 5.17.F8;
(f) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 56 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 58 of 5.19.F12;
(g) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 65 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 67 of 5.23.C9;
(h) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 74 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 76 of 5.23.C12;
(i) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 83 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 85 of 8.51.G11;
(j) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 92 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 94 of 9.51.H9;
(k) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 101 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 103 of 18.43.D8;
(l) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 110 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 112 of 22.22.E7;
(m) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 149 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 151 of 8.51.G10;
(n) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 153 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 155 of 5.24A.A7;
(o) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 157 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 159 of 5.24A.F3;
(p) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 161 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 163 of 5.8B.H4;
(q) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 165 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 167 of 26.51.E1;
(r) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 169 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 171 of 22.21.A7;
(s) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 177 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 179 of 5.52.H10;
(t) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 181 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 183 of 5.15.C1;
(u) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 185 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 187 of 5.54.E6;
(v) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 189 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 191 of 5.55.D2;
(w) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 193 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 195 of 22.14.A1;
(x) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 197 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 199 of 26.53.B4;
(y) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 201 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 203 of 5.63.E2;
(z) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 205 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 207 of 5.64.G4;
(aa) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 209 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 211 of 43.52.A11;
(ab) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 213 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 215 of 43.52.E12; and
(ac) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 217 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 219 of 43.62.E2.

### Claim 60 (depends on 45)

The method of claim 45, wherein at least one of the antibodies in the antibody mixture is selected from the group consisting of:
(a) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 11 (5.11.H10), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 13 (5.11.H10);
(b) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20 (5.27.A11), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 22 (5.27.A11);
(c) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38 (5.6.H9), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 40 (5.6.H9);
(d) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 47 (5.17.F8), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 49 (5.17.F8);
(e) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56 (5.19.F12), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 58 (5.19.F12);
(f) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 65 (5.23.C9), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 67 (5.23.C9);
(g) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 74 (5.23.C12), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 76 (5.23.C12);
(h) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83 (8.51.G11), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 85 (8.51.G11);
(i) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 92 (9.51.H9), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 94 (9.51.H9);
(j) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 101 (18.43.D8), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 103 (18.43.D8);
(k) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 110 (22.22.E7), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 112 (22.22.E7);
(l) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 149(8.51.G10), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 151 (8.51.G10);
(m) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 153 (5.24A.A7), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 155 (5.24A.A7);
(n) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 157 (5.24A.F3), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 159 (5.24A.F3);
(o) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 161 (5.8B.H4), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 163 (5.8B.H4);
(p) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 165 (26.51.E1), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 167 (26.51.E1);
(q) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 169 (22.21.A7), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 171 (22.21.A7);
(r) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 173 (22.18A.E9), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 175 (22.18A.E9);
(s) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 177 (5.52.H10), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 179 (5.52.H10);
(t) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 181 (5.15.C1), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 191 (5.15.C1);
(u) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 185 (5.54.E6), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 187 (5.54.E6);
(v) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 189 (5.55.D2), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 191 (5.55.D2);
(w) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 193 (22.14.A1), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 195 (22.14.A1); and
(x) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 197 (26.53.B4), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 199 (26.53.B4);
(y) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 201 (5.63.E2), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 203 (5.63.E2);
(z) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 205 (5.64.G4), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 207 (5.64.G4);
(aa) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 209 (43.52.A11), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 211 (43.52.A11);
(ab) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 213 (43.52.E12), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 215 (43.52.E12); and
(ac) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 217 (43.62.E2), and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 219 (43.62.E2).

### Claim 61

An anti-Staphylococcus aureus (S. aureus) antibody or antigen-binding fragment thereof selected from the group consisting of:
(a) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 38 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 40 of 5.6.H9;
(b) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 173 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 175 of 22.18A.E9;
(c) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 11 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 13 of 5.11.H10;
(d) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 20 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 22 of 5.27.A11;
(e) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 47 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 49 of 5.17.F8;
(f) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 56 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 58 of 5.19.F12;
(g) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 65 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 67 of 5.23.C9;
(h) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 74 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 76 of 5.23.C12;
(i) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 83 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 85 of 8.51.G11;
(j) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 92 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 94 of 9.51.H9;
(k) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 101 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 103 of 18.43.D8;
(l) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 110 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 112 of 22.22.E7;
(m) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 149 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 151 of 8.51.G10;
(n) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 153 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 155 of 5.24A.A7;
(o) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 157 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 159 of 5.24A.F3;
(p) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 161 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 163 of 5.8B.H4;
(q) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 165 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 167 of 26.51.E1;
(r) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 169 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 171 of 22.21.A7;
(s) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 177 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 179 of 5.52.H10;
(t) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 181 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 183 of 5.15.C1;
(u) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 185 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 187 of 5.54.E6;
(v) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 189 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 191 of 5.55.D2;
(w) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 193 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 195 of 22.14.A1;
(x) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 197 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 199 of 26.53.B4;
(y) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 201 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 203 of 5.63.E2;
(z) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 205 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 207 of 5.64.G4;
(aa) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 209 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 211 of 43.52.A11;
(ab) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 213 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 215 of 43.52.E12; and
(ac) an antibody comprising CDR1, CDR2 and CDR3 of heavy chain amino acid sequence SEQ ID NO: 217 and CDR1, CDR2, CDR3 of light chain amino acid sequence SEQ ID NO: 219 of 43.62.E2.

### Claim 62

An anti-Staphylococcus aureus (S. aureus) human monoclonal antibody selected from the antibodies listed in Table 2.

### Claim 63

A monoclonal antibody mixture that neutralizes Staphylococcus aureus (S. aureus) or a toxin, cell surface antigen or immunomodulating agent thereof, the mixture comprising at least two antibodies as set forth in Table 1 and combinations thereof.

### Claim 64 (depends on 45)

The Method of claim 45, wherein the Staphylococcus aureus infection is an infection resulting from one or more strains of antibiotic-resistant Staphylococcus aureus.
